JPS6117A - ムコ多糖系癌転移抑制剤 - Google Patents

ムコ多糖系癌転移抑制剤

Info

Publication number
JPS6117A
JPS6117A JP11828384A JP11828384A JPS6117A JP S6117 A JPS6117 A JP S6117A JP 11828384 A JP11828384 A JP 11828384A JP 11828384 A JP11828384 A JP 11828384A JP S6117 A JPS6117 A JP S6117A
Authority
JP
Japan
Prior art keywords
crosslinked
cells
molecular weight
salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP11828384A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0456805B2 (fr
Inventor
Katsukiyo Sakurai
桜井　勝清
Katsuyuki Horie
克之 堀江
Takashi Sakamoto
崇 坂本
Takashi Okuyama
隆 奥山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Priority to JP11828384A priority Critical patent/JPS6117A/ja
Publication of JPS6117A publication Critical patent/JPS6117A/ja
Publication of JPH0456805B2 publication Critical patent/JPH0456805B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP11828384A 1984-06-11 1984-06-11 ムコ多糖系癌転移抑制剤 Granted JPS6117A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11828384A JPS6117A (ja) 1984-06-11 1984-06-11 ムコ多糖系癌転移抑制剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11828384A JPS6117A (ja) 1984-06-11 1984-06-11 ムコ多糖系癌転移抑制剤

Publications (2)

Publication Number Publication Date
JPS6117A true JPS6117A (ja) 1986-01-06
JPH0456805B2 JPH0456805B2 (fr) 1992-09-09

Family

ID=14732832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11828384A Granted JPS6117A (ja) 1984-06-11 1984-06-11 ムコ多糖系癌転移抑制剤

Country Status (1)

Country Link
JP (1) JPS6117A (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001280A1 (fr) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Derives de glycosaminoglycane et leur utilisation comme inhibiteurs de l'invasion tumorale ou proliferation metastatique
JPS63502670A (ja) * 1986-03-14 1988-10-06 バイオ−テクノロジ−・ジエネラル・コ−ポレイシヨン 抗菌物質として有効なヒアルロン酸の重金属塩
WO1991013624A1 (fr) * 1990-03-05 1991-09-19 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Glycosaminoglycans sulfates endogenes induits par suramine, utilises comme agents anti-cancereux chez l'homme
WO1992001720A1 (fr) * 1990-07-24 1992-02-06 Seikagaku Kogyo Kabushiki Kaisha Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
WO1994020115A2 (fr) * 1993-03-10 1994-09-15 Miles, Inc. Acide hyaluronique utilise comme traitement contre le cancer
LT3545B (en) 1989-09-21 1995-11-27 Norpharmco Inc Compositions of medicinal preparation and hyaluronic acid for treatment of conditions and disease
US5614506A (en) * 1991-07-03 1997-03-25 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5674857A (en) * 1992-02-20 1997-10-07 Hyal Pharmaceutical Corporation Use of hyaluronic acid to repair ischemia reperfusion damage
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
WO1997040841A1 (fr) * 1996-04-29 1997-11-06 Hyal Pharmaceutical Corporation Emploi de formes d'acide hyaluronique (ha) pour therapie anticancereuse
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
WO1998016559A1 (fr) * 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
WO1999006114A3 (fr) * 1997-07-31 1999-04-08 Geistlich Soehne Ag Utilisation de taurolidine ou de taurultane pour produire un medicament permettant de prevenir des metastases
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
EP1393749A1 (fr) * 2002-08-30 2004-03-03 Petrigni, Giuseppe Préparation pharmaceutique en forme colloidale pour le traitement des maladies de la peau, comprenant de l' acide hyluronique
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
US6852255B2 (en) * 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides
JP2005524619A (ja) * 2002-01-11 2005-08-18 フィディーア・ファルマチェウティチ・ソシエタ・ペル・アチオニ 腫瘍の処置における抗血管形成療法のためのヒアルロン酸に基づくバイオマテリアル
EP1301209A4 (fr) * 2000-07-14 2005-11-09 Meditech Res Ltd Hyaluronan utilise comme agent cytotoxique, pre-sensibilisateur a des medicaments et chimio-sensibilisateur dans le traitement de maladies
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7910580B2 (en) 1999-06-04 2011-03-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8741970B2 (en) 1999-01-13 2014-06-03 Alchemia Oncology Pty Limited Composition and method for the enhancement of the efficacy of drugs
US8758819B2 (en) 2006-09-13 2014-06-24 Enhance Skin Products, Inc. Cosmetic compositions for the treatment of skin and methods thereof
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS63502670A (ja) * 1986-03-14 1988-10-06 バイオ−テクノロジ−・ジエネラル・コ−ポレイシヨン 抗菌物質として有効なヒアルロン酸の重金属塩
WO1988001280A1 (fr) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Derives de glycosaminoglycane et leur utilisation comme inhibiteurs de l'invasion tumorale ou proliferation metastatique
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
US5985850A (en) * 1989-09-21 1999-11-16 Hyal Pharmaceuticals Corporation Compositions comprising hyaluronic acid and drugs
US5929048A (en) * 1989-09-21 1999-07-27 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US6048844A (en) * 1989-09-21 2000-04-11 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5985851A (en) * 1989-09-21 1999-11-16 Hyal Pharmaceutical Corporation Use of hyaluronic acid or its derivatives in peritoneal dialysis and formulations thereof
US5811410A (en) * 1989-09-21 1998-09-22 Hyal Pharmaceutical Corporation Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID
LT3545B (en) 1989-09-21 1995-11-27 Norpharmco Inc Compositions of medicinal preparation and hyaluronic acid for treatment of conditions and disease
US5932560A (en) * 1989-09-21 1999-08-03 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US6069135A (en) * 1989-09-21 2000-05-30 Hyal Pharmaceutical Corporation Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
US5914314A (en) * 1989-09-21 1999-06-22 Hyal Pharmaceutical Corporation Use of a form of hyaluronic acid and a medicinal agent for reducing rejection of organs transplantation in mammals
US5852002A (en) * 1989-09-21 1998-12-22 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US6194392B1 (en) 1989-09-21 2001-02-27 Hyal Pharmaceutical Corporation Treatment of conditions and disease
US5830882A (en) * 1989-09-21 1998-11-03 Hyal Pharmaceutical Corporation Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition
US5827834A (en) * 1989-09-21 1998-10-27 Hyal Pharmaceutical Corporation Method of using hyaluronic acid or its pharmaceutically acceptable salts for the treatment of disease
WO1991013624A1 (fr) * 1990-03-05 1991-09-19 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Glycosaminoglycans sulfates endogenes induits par suramine, utilises comme agents anti-cancereux chez l'homme
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
EP0493622A1 (fr) * 1990-07-24 1992-07-08 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer
WO1992001720A1 (fr) * 1990-07-24 1992-02-06 Seikagaku Kogyo Kabushiki Kaisha Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
EP0493622B1 (fr) * 1990-07-24 1997-02-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5614506A (en) * 1991-07-03 1997-03-25 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5914322A (en) * 1992-02-20 1999-06-22 Hyal Pharmaceutical Corporation Treatment of disease and conditions
US5674857A (en) * 1992-02-20 1997-10-07 Hyal Pharmaceutical Corporation Use of hyaluronic acid to repair ischemia reperfusion damage
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1994020115A3 (fr) * 1993-03-10 1994-11-10 Miles Inc Acide hyaluronique utilise comme traitement contre le cancer
WO1994020115A2 (fr) * 1993-03-10 1994-09-15 Miles, Inc. Acide hyaluronique utilise comme traitement contre le cancer
WO1997040841A1 (fr) * 1996-04-29 1997-11-06 Hyal Pharmaceutical Corporation Emploi de formes d'acide hyaluronique (ha) pour therapie anticancereuse
WO1998016559A1 (fr) * 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
WO1999006114A3 (fr) * 1997-07-31 1999-04-08 Geistlich Soehne Ag Utilisation de taurolidine ou de taurultane pour produire un medicament permettant de prevenir des metastases
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US8741970B2 (en) 1999-01-13 2014-06-03 Alchemia Oncology Pty Limited Composition and method for the enhancement of the efficacy of drugs
US7910580B2 (en) 1999-06-04 2011-03-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-Fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US9012444B2 (en) 1999-06-04 2015-04-21 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
US8287894B2 (en) 2000-07-14 2012-10-16 Alchemia Oncology Pty Limited Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1301209A4 (fr) * 2000-07-14 2005-11-09 Meditech Res Ltd Hyaluronan utilise comme agent cytotoxique, pre-sensibilisateur a des medicaments et chimio-sensibilisateur dans le traitement de maladies
JP2012162569A (ja) * 2000-07-14 2012-08-30 Alchemia Oncology Pty Ltd 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン
US8388993B2 (en) 2000-07-14 2013-03-05 Alchemia Oncology Pty Limited Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6852255B2 (en) * 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides
US7338943B2 (en) 2001-12-21 2008-03-04 Soft Gel Technologies, Inc. Hyaluronic acid in soft gel form
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
US8551975B1 (en) 2001-12-21 2013-10-08 Soft Gel Technologies, Inc. Hyaluronic acid in soft gel form
US7008932B2 (en) * 2001-12-21 2006-03-07 Soft Gel Technologies, Inc. Hyaluronic acid in soft gel form
JP2005524619A (ja) * 2002-01-11 2005-08-18 フィディーア・ファルマチェウティチ・ソシエタ・ペル・アチオニ 腫瘍の処置における抗血管形成療法のためのヒアルロン酸に基づくバイオマテリアル
US7838510B2 (en) * 2002-01-11 2010-11-23 Fidia Farmaceutici S.P.A. Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors
EP1393749A1 (fr) * 2002-08-30 2004-03-03 Petrigni, Giuseppe Préparation pharmaceutique en forme colloidale pour le traitement des maladies de la peau, comprenant de l' acide hyluronique
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8758819B2 (en) 2006-09-13 2014-06-24 Enhance Skin Products, Inc. Cosmetic compositions for the treatment of skin and methods thereof

Also Published As

Publication number Publication date
JPH0456805B2 (fr) 1992-09-09

Similar Documents

Publication Publication Date Title
JPS6117A (ja) ムコ多糖系癌転移抑制剤
JP2806454B2 (ja) 脈管形成阻止剤
US5250519A (en) Non-anticoagulant heparin derivatives
US5895784A (en) Method for treatment of cancer by oral administration of modified pectin
US4945086A (en) Smooth muscle cell growth inhibitor
JPS6218401A (ja) 結合組織病理において有効な医薬の製造に使用する多糖およびオリゴ糖
SK459890A3 (en) USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT
JPH01503548A (ja) ヘパリン誘導体
US7005426B2 (en) Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component
US11419891B2 (en) High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
JP6741277B2 (ja) 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用
JPH027577B2 (fr)
WO2005092348A1 (fr) Accélérateur de production hgf contenant un oligosaccharide de type héparine
Aguado et al. Salmonella infections of the abdominal aorta cured with prolonged antibiotic treatment
Shimamoto et al. Myocardial infarct-like lesions and arteriosclerosis induced by high molecular substances, and prevention by magnesium salt
WO1999026984A1 (fr) Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau
NZ500527A (en) Use of pentosan polysulfate (PPS) for treating chronic progressive vascular scarring diseases
Bertolesi et al. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins
JPS58141785A (ja) 抗腫瘍物質の製法
WO1994008595A1 (fr) Utilisation d'heparine non anticoagulante dans le traitement des lesions ischemiques et consecutives a une perfusion
Barry et al. Anticancer Agents: I. Structure-Activity Relationships in a Series of Oxypolysaccharide-Thiosemicarbazide Derivatives
JP2583183B2 (ja) 生理活性を有するグリコーゲンの製法及び生理活性
JP4633232B2 (ja) 成長因子誘導剤
Tian et al. Novel silk protein/hyaluronic acid hydrogel loaded with azithromycin as an immunomodulatory barrier to prevent postoperative adhesions
JPS61210034A (ja) 関節症治療剤

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees